LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

LLY

987.98

+2.24%↑

JNJ

224.37

+1.35%↑

ABBV

207.85

+2.48%↑

UNH

396.24

+3.1%↑

AZN

184.48

+1.46%↑

Search

Karyopharm Therapeutics Inc

Closed

SectorHealthcare

8.88 1.25

Overview

Share price change

24h

Current

Min

8.69

Max

9.17

Key metrics

By Trading Economics

Income

-69M

-102M

Sales

-10M

34M

EPS

-5.69

Profit margin

-299.886

Employees

228

EBITDA

4.7M

-18M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+99.77% upside

Market Stats

By TradingEconomics

Market Cap

53M

210M

Previous open

7.63

Previous close

8.88

News Sentiment

By Acuity

16%

84%

22 / 346 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bullish Evidence

Karyopharm Therapeutics Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

12 maj 2026, 22:50 UTC

Earnings

Commonwealth Bank of Australia Increases Provisions as 3Q Profit Slips

12 maj 2026, 22:49 UTC

Earnings

Aristocrat Leisure Raises Midyear Dividend, Swells Share Buyback Program

12 maj 2026, 22:32 UTC

Earnings

JBS 1Q Profit Slides Amid Rising Cattle Costs -- Update

12 maj 2026, 23:48 UTC

Market Talk

Nikkei May Decline Amid Uncertainty Over Iran Conflict -- Market Talk

12 maj 2026, 22:57 UTC

Market Talk
Earnings

JBS Says Consumers Are Looking to Pork for Affordable Protein -- Market Talk

12 maj 2026, 22:26 UTC

Earnings

Aristocrat Leisure to Increase On-Market Share Buyback by A$1 Billion

12 maj 2026, 22:25 UTC

Earnings

Aristocrat Leisure 1H Normalized Pretax Profit A$997.3 Million, Up 9.4% on Year

12 maj 2026, 22:25 UTC

Earnings

Aristocrat Leisure Interim Dividend A$0.50/Security

12 maj 2026, 22:24 UTC

Earnings

Aristocrat Leisure 1H Revenue From Continuing Operations A$3.03 Billion, Down 0.2% on Year

12 maj 2026, 22:23 UTC

Earnings

Aristocrat Leisure 1H Net Profit From Discontinued Operations A$7.0 Million

12 maj 2026, 22:23 UTC

Earnings

Aristocrat Leisure 1H Net Profit From Continuing Operations A$798.5 Million, Up 56%

12 maj 2026, 22:19 UTC

Earnings

CBA: Total Provision Coverage Ratio 1.57%>CBA.AU

12 maj 2026, 22:14 UTC

Earnings

CBA: Business Lending Continued to Grow Above System>CBA.AU

12 maj 2026, 22:14 UTC

Earnings

CBA Had 1.4M Business Transaction Accounts at March 31, Up 7% on Year>CBA.AU

12 maj 2026, 22:13 UTC

Earnings

CBA Household Deposits Grew A$38B in 12 Months Through March>CBA.AU

12 maj 2026, 22:12 UTC

Earnings

CBA Home Loan Balances Grew A$41B in 12 Months Through March>CBA.AU

12 maj 2026, 22:12 UTC

Earnings

CBA 3Q New Home Loan Funding A$45B>CBA.AU

12 maj 2026, 22:11 UTC

Earnings

Correct: JBS NV 1Q EPS 20c, Not 21c >JBS

12 maj 2026, 22:11 UTC

Earnings

CBA: CET1 Level 2 Capital Ratio 11.6%>CBA.AU

12 maj 2026, 22:10 UTC

Earnings

CBA: Customer Deposit Funding Ratio 79%>CBA.AU

12 maj 2026, 22:09 UTC

Earnings

CBA: Underlying Portfolio Credit Quality Remains Sound>CBA.AU

12 maj 2026, 22:09 UTC

Earnings

CBA: Higher Collective Provisions Reflect Geopolitical, Macroeconomic Uncertainty >CBA.AU

12 maj 2026, 22:08 UTC

Earnings

CBA 3Q Loan Impairment Expense A$316M>CBA.AU

12 maj 2026, 22:07 UTC

Earnings

CBA: Costs Up on Higher Cloud Computing Volumes, Software Licenses, AI Investment>CBA.AU

12 maj 2026, 22:06 UTC

Earnings

CBA 3Q Operating Expenses Up 1% Excluding Restructuring, Notable Items>CBA.AU

12 maj 2026, 22:06 UTC

Earnings

CBA: 3Q Underlying Net Interest Margin Was Broadly Stable>CBA.AU

12 maj 2026, 22:05 UTC

Earnings

CBA: Lending, Deposit Volume Growth Offset Impact of Two Fewer Days >CBA.AU

12 maj 2026, 22:04 UTC

Earnings

Commonwealth Bank: Operating Income Flat in March Quarter >CBA.AU

12 maj 2026, 22:04 UTC

Earnings

Commonwealth Bank 3Q Cash Profit Up 4% on Year>CBA.AU

12 maj 2026, 22:04 UTC

Earnings

Commonwealth Bank 3Q Cash Profit Down 1% on 1H Quarterly Average>CBA.AU

Peer Comparison

Price change

Karyopharm Therapeutics Inc Forecast

Price Target

By TipRanks

99.77% upside

12 Months Forecast

Average 17.6 USD  99.77%

High 28 USD

Low 13 USD

Based on 6 Wall Street analysts offering 12 month price targets forKaryopharm Therapeutics Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

6 ratings

6

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

5.9501 / 7.66Support & Resistance

Short Term

Bullish Evidence

Intermediate Term

Strong Bearish Evidence

Long Term

No Evidence

Sentiment

By Acuity

22 / 346 Ranking in Healthcare

News Sentiment

Very Strong Bullish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

help-icon Live chat